Page last updated: 2024-11-11

hypoxoside

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

hypoxoside: RN given for (E)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID13785311
MeSH IDM0232796

Synonyms (3)

Synonym
hypoxoside
(1e)-1-penten-4-yne-1,5-diylbis(2-hydroxy-4,1-phenylene) bis-|a-d-glucopyranoside
(2s,3r,4s,5s,6r)-2-[2-hydroxy-4-[(e)-5-[3-hydroxy-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]pent-1-en-4-ynyl]phenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" No toxic effects, in clinical examinations or biochemical or haematological measurements, were found that could be ascribed to the ingestion of hypoxoside."( A phase I trial of hypoxoside as an oral prodrug for cancer therapy--absence of toxicity.
Albrecht, CF; Bouic, PJ; Etsebeth, S; Freestone, M; Gouws, L; Kruger, PB; Liebenberg, RW; Smit, BJ; Theron, E; van Jaarsveld, PP, 1995
)
0.29

Pharmacokinetics

hypoxoside was found to be deconjugated by bacterial beta-glucosidase to form rooperol in the colon.

ExcerptReferenceRelevance
" Pharmacokinetic studies on mice dosed intragastrically with hypoxoside showed that it was deconjugated by bacterial beta-glucosidase to form rooperol in the colon."( Morphological characterisation of the cell-growth inhibitory activity of rooperol and pharmacokinetic aspects of hypoxoside as an oral prodrug for cancer therapy.
Albrecht, CF; Kruger, PB; Theron, EJ, 1995
)
0.29
"To study the pharmacokinetic behaviour of hypoxoside taken orally by 24 patients with lung cancer."( The pharmacokinetic behaviour of hypoxoside taken orally by patients with lung cancer in a phase I trial.
Albrecht, CF; Freestone, M; Gouws, L; Kruger, PB; Miller, R; Smit, BJ; van Jaarsveld, PP, 1995
)
0.29
"This study concerns the pharmacokinetic behaviour and cardiovascular effects of rapid infusions of hypoxoside (CAS 83643-94-1) and rooperol (CAS 83644-00-2) in anaesthetised Chacma baboons."( Pharmacokinetic behaviour and cardiovascular effects of intravenously administered hypoxoside and rooperol.
Albrecht, CF; Coetzee, JF; Jahed, N; Kruger, PB; van Jaarsveld, PP, 1996
)
0.29

Dosage Studied

ExcerptRelevanceReference
" Pharmacokinetic studies on mice dosed intragastrically with hypoxoside showed that it was deconjugated by bacterial beta-glucosidase to form rooperol in the colon."( Morphological characterisation of the cell-growth inhibitory activity of rooperol and pharmacokinetic aspects of hypoxoside as an oral prodrug for cancer therapy.
Albrecht, CF; Kruger, PB; Theron, EJ, 1995
)
0.29
" Lopinavir plasma exposure as estimated by the area under the concentration-time curve over the 12-h dosing interval (AUC(0-12h), AUCĪ„) was determined on day 14 and again on day 21."( Co-administration of a commonly used Zimbabwean herbal treatment (African potato) does not alter the pharmacokinetics of lopinavir/ritonavir.
Aweeka, F; Greenblatt, R; Guglielmo, BJ; Gwaza, L; Huang, L; Lizak, P, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (31.58)18.2507
2000's6 (31.58)29.6817
2010's7 (36.84)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (15.00%)5.53%
Reviews1 (5.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]